Skip to main content

Novavax says vaccine targeting Covid and flu shows promising results in early data

Novavax plans to move forward with a phase two trial this year to confirm the dosing levels, and a phase three during the 2023 flu season at the earliest.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.